All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000134-37 | Trial to Reduce Cardiovascular Events with Aranesp Therapy | 2009-07-23 | due-trials |
| Reported results | 2004-000138-35 | A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis | 2008-10-14 | due-trials |
| Reported results | 2004-000172-13 | AN OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF LONG-TERM DOSING OF AMG 531 IN THROMBOCYTOPENIC SUBJECTS WITH IMMUNE (IDIOPATHIC) THROMBOCITOPENIC PURPURA Studio in aperto per valutare la... | 2010-01-26 | due-trials |
| Reported results | 2004-000173-65 | A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy | 2006-12-27 | due-trials |
| Reported results | 2004-000174-31 | A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splene... | 2006-11-01 | due-trials |
| Reported results | 2004-000509-24 | A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy | 2006-06-15 | due-trials |
| Completed, but no date, and reported results | 2004-000511-25 | A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates | bad-data | |
| Reported results | 2004-000512-17 | A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer | 2008-05-14 | due-trials |
| Exempt | 2004-000645-37 | A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-myeloid Malignancies... | not-yet-due | |
| Reported results | 2004-001154-86 | A Multicenter, Double-blind, Placebo-controlled Roll-over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer | 2007-01-17 | due-trials |
| Reported results | 2004-001417-33 | A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy | 2006-08-01 | due-trials |
| Reported results | 2004-002016-28 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction... | 2016-07-11 | due-trials |
| Reported results | 2004-002165-20 | An Open Label Study of AMG 706 in Subjects with Advanced Gastrointestinal Stromal Tumors (GISTs) who Developed Progressive Disease or Relapsed While on Imatinib Mesylate | 2007-03-07 | due-trials |
| Reported results | 2004-002310-10 | Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism | 2005-11-10 | due-trials |
| Reported results | 2004-004178-10 | A Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the... | 2006-08-28 | due-trials |
| Reported results | 2004-004499-35 | A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects with Chronic Kidney Disease Receiving Haemodialysis | 2006-10-05 | due-trials |
| Ongoing | 2004-004558-18 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis | not-yet-due | |
| Reported results | 2004-005007-14 | A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With St... | 2014-03-31 | due-trials |
| Exempt, with results | 2004-005252-14 | Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI): Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronar... | 2006-11-28 | not-yet-due |
| Reported results | 2005-000213-35 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction... | 2017-07-11 | due-trials |
| Reported results | 2005-001618-42 | A Phase 2 Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer | 2007-03-13 | due-trials |
| Reported results | 2005-003558-83 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis. | 2008-02-06 | due-trials |
| Reported results | 2005-004323-18 | An Open Label Study Treatment Extension Study of AMG 706 Studio in aperto di estensione del trattamento con AMG706 | 2012-07-16 | due-trials |
| Reported results | 2005-004642-14 | Estudio abierto, de un solo grupo, de palifermin para la reducción de la mucositis en sujetos con linfoma no Hodgkin (LNH) o mieloma múltiple (MM) sometidos a quimioterapia a altas dosis y trasplante ... | 2007-04-26 | due-trials |
| Reported results | 2005-004643-53 | Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease | 2011-05-13 | due-trials |
| Reported results | 2005-004676-20 | "A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Co... | 2010-09-13 | due-trials |
| Reported results | 2005-005081-37 | A Randomized, Double-Blind Study to Compare the Efficacy of Treatment with Denosumab versus Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density | 2007-12-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-005271-15 | A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Densi... | bad-data | |
| Reported results | 2005-005275-15 | A Randomized, Double- Blind, Placebo- Controlled, Multi- Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects with Non- Metastatic Breast Cancer Receiving Aromatase Inhibito... | 2022-07-26 | due-trials |
| Reported results | 2005-005278-59 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptom... | 2012-10-11 | due-trials |
| Reported results | 2005-005484-28 | A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab | 2011-11-14 | due-trials |
| Reported results | 2005-005485-37 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-refractory Prostate Cancer | 2014-04-09 | due-trials |
| Reported results | 2006-000074-79 | A Multicenter, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis | 2007-06-05 | due-trials |
| Reported results | 2006-000091-32 | A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women with H... | 2012-05-30 | due-trials |
| Reported results | 2006-000144-92 | An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | 2008-06-10 | due-trials |
| Reported results | 2006-000170-70 | A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin... | 2013-01-24 | due-trials |
| Reported results | 2006-000339-93 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer | 2012-04-04 | due-trials |
| Reported results | 2006-000341-19 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer Studio M... | 2012-02-27 | due-trials |
| Reported results | 2006-000848-65 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa 63720; in the Treatment of Bone Metastases in Subjects with Advanced Cancer Excluding Breast and Pro... | 2011-08-24 | due-trials |
| Reported results | 2006-000849-19 | A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density | 2008-03-18 | due-trials |
| Reported results | 2006-002075-40 | EVOLVE Evaluation of Cinacalcet HCI Therapy to lower CardioVascular events. | 2012-03-21 | due-trials |
| Reported results | 2006-002662-19 | A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Studio randomizzato... | 2009-05-15 | due-trials |
| Reported results | 2006-003173-27 | A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis | 2012-04-10 | due-trials |
| Reported results | 2006-003698-29 | A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis | 2008-06-11 | due-trials |
| Reported results | 2006-003699-36 | A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subje... | 2008-12-02 | due-trials |
| Reported results | 2006-003700-18 | A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopath... | 2009-11-05 | due-trials |
| Reported results | 2006-003709-15 | A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj... | 2011-11-22 | due-trials |
| Reported results | 2006-003784-32 | A Phase 3, Multicenter, Randomized, Placebo Controlled, Double Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non small Cell Lung Cancer | 2012-12-14 | due-trials |
| Completed, but no date, and reported results | 2006-003785-33 | A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma | bad-data | |
| Reported results | 2006-003786-13 | A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | 2012-03-12 | due-trials |
| Reported results | 2006-006520-19 | An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of positi... | 2014-11-26 | due-trials |
| Exempt, with results | 2006-006658-89 | A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | 2011-03-23 | not-yet-due |
| Reported results | 2006-006739-36 | A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancer | 2012-08-02 | due-trials |
| Reported results | 2006-006964-48 | An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone | 2010-11-16 | due-trials |
| Reported results | 2007-000147-98 | A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastat... | 2014-06-10 | due-trials |
| Reported results | 2007-000570-22 | A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer | 2008-01-10 | due-trials |
| Reported results | 2007-000573-29 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism | 2013-06-17 | due-trials |
| Reported results | 2007-000638-37 | An Open Label Study of AMG 531 in Severely Refractory Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | 2011-01-05 | due-trials |
| Reported results | 2007-001041-17 | An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis | 2015-07-29 | due-trials |
| Reported results | 2007-001438-15 | A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | 2011-12-16 | due-trials |
| Reported results | 2007-001439-74 | A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | 2011-04-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-001516-24 | An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS) | 2012-06-12 | bad-data |
| Reported results | 2007-003384-51 | A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG386 plus Paclitaxel as First-Line Therapy in Subjects with Her2-Negative, Metastat... | 2014-05-19 | due-trials |
| Reported results | 2007-003569-42 | Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 1/2 para Determinar la Seguridad y la Eficacia de AMG 531 en Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica Inmu... | 2009-03-03 | due-trials |
| Reported results | 2007-003573-50 | A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in Sub... | 2012-06-06 | due-trials |
| Reported results | 2007-004722-25 | A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer | 2010-11-04 | due-trials |
| Reported results | 2007-005722-79 | A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and ... | 2014-03-06 | due-trials |
| Reported results | 2007-005792-34 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 μg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced ... | 2018-06-05 | due-trials |
| Reported results | 2007-006050-25 | An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metas... | 2011-09-23 | due-trials |
| Reported results | 2007-007258-75 | A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome... | 2015-12-10 | due-trials |
| Reported results | 2008-001605-42 | A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Effica... | 2013-06-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-001606-16 | An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone | 2018-05-17 | bad-data |
| Completed, but no date, and reported results | 2008-001721-34 | A Phase 2, Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Darbepoetin alfa for the Treatment of Anemia in Paediatric Subjects with Solid Tumours Receiving Cyclic Chemotherapy | bad-data | |
| Reported results | 2008-001751-21 | A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer | 2013-10-31 | due-trials |
| Reported results | 2008-003258-14 | A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of AMG 386 in Combination with FOLFIRI in Subjects with Previously Treated Metastatic Colorectal Carcinoma | 2012-05-16 | due-trials |
| Reported results | 2008-003292-42 | A Phase 1b/ 2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer | 2013-02-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-003418-88 | A Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Rec... | 2014-03-03 | bad-data |
| Reported results | 2008-004281-71 | A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously U... | 2016-07-16 | due-trials |
| Reported results | 2008-004347-10 | A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Imm... | 2014-01-09 | due-trials |
| Exempt, with results | 2008-004355-30 | A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer | 2012-04-30 | not-yet-due |
| Reported results | 2008-004438-25 | A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | 2019-12-09 | due-trials |
| Reported results | 2008-004558-34 | Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Ini... | 2012-12-21 | due-trials |
| Reported results | 2008-004752-77 | A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irino... | 2022-07-22 | due-trials |
| Exempt, with results | 2008-005074-12 | A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Estud... | 2011-08-10 | not-yet-due |
| Reported results | 2008-005140-16 | Inhibición de la Delta-PROTEína cinasa C para la reducCCIÓN del tamaño del infarto en Infarto Agudo de Miocardio (PROTECCIÓN IAM) Inhibition of Delta-PROTEin kinase C for the reducTION of infarct size... | 2011-06-17 | due-trials |
| Reported results | 2008-005301-19 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-... | 2012-06-04 | due-trials |
| Reported results | 2008-005991-28 | A Randomized, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women with Low Bone Mineral Density | 2016-02-03 | due-trials |
| Reported results | 2008-006154-17 | An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic P... | 2012-05-13 | due-trials |
| Reported results | 2008-006210-14 | Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic ... | 2019-06-24 | due-trials |
| Reported results | 2008-006212-38 | Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma. | 2015-06-21 | due-trials |
| Reported results | 2008-008392-34 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation wi... | 2013-07-11 | due-trials |
| Reported results | 2009-009374-27 | An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma | 2012-04-28 | due-trials |
| Reported results | 2009-009756-21 | A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonate... | 2013-08-21 | due-trials |
| Reported results | 2009-010205-37 | A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab versus Placebo in Males with Low Bone Mineral Density | 2012-05-23 | due-trials |
| Reported results | 2009-010587-42 | A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy. | 2012-01-17 | due-trials |
| Reported results | 2009-010715-32 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | 2017-07-22 | due-trials |
| Reported results | 2009-010726-19 | A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates. | 2011-11-09 | due-trials |
| Reported results | 2009-011299-32 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence | 2018-03-26 | due-trials |
| Reported results | 2009-011899-30 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizuma... | 2015-01-02 | due-trials |
| Reported results | 2009-012076-26 | A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation ... | 2016-05-12 | due-trials |
| Reported results | 2009-012566-32 | A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Me... | 2011-02-11 | due-trials |
| Reported results | 2009-012943-41 | A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo P... | 2012-12-21 | due-trials |
| Reported results | 2009-013538-26 | A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma | 2010-12-13 | due-trials |
| Reported results | 2009-013539-39 | A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis | 2010-09-27 | due-trials |
| Reported results | 2009-015939-33 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Pr... | 2013-05-20 | due-trials |
| Completed, but no date, and reported results | 2009-015989-62 | An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute... | bad-data | |
| Reported results | 2009-016119-38 | A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis. | 2011-04-06 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-016163-12 | A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis. | bad-data | |
| Trial is partly outside EEC, and reported results | 2009-016203-32 | An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) | 2017-01-12 | bad-data |
| Reported results | 2009-016522-14 | A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Studio mul... | 2017-09-22 | due-trials |
| Reported results | 2009-017946-30 | A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary... | 2017-04-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-017999-25 | An Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to < 6 Years with Chronic Kidney Disea... | 2015-09-23 | bad-data |
| Reported results | 2010-018314-75 | A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acu... | 2019-01-07 | due-trials |
| Trial is outside EEC, and reported results | 2010-018426-39 | A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia (ITP) | bad-data | |
| Reported results | 2010-019543-19 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects wth Inadequately Controlled Asthma | 2011-12-21 | due-trials |
| Reported results | 2010-019544-39 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease | 2011-10-15 | due-trials |
| Reported results | 2010-019821-32 | A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fal... | 2016-12-16 | due-trials |
| Reported results | 2010-019987-35 | A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim. | 2013-12-26 | due-trials |
| Reported results | 2010-020398-18 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas | 2012-12-12 | due-trials |
| Reported results | 2010-020454-34 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma Studio multicent... | 2019-03-29 | due-trials |
| Completed, but no date, and reported results Terminated | 2010-020881-53 | A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease | bad-data | |
| Reported results | 2010-021003-24 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfun... | 2013-04-18 | due-trials |
| Reported results | 2010-021846-23 | An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer | 2014-02-21 | due-trials |
| Reported results | 2010-022270-14 | Estudio abierto de extensión de fase 2 con conatumumab . A Phase 2 Open Label Extension Study of Conatumumab. | 2020-02-05 | due-trials |
| Reported results | 2010-022951-49 | A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory ... | 2016-11-08 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-023150-37 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving D... | 2014-02-14 | bad-data |
| Reported results | 2010-023978-39 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma... | 2012-12-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-024264-18 | A Single-Arm Multicenter Phase II Study preceded by Dose Evalua-tion to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Pati... | 2016-06-20 | bad-data |
| Reported results | 2010-024393-19 | A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals | 2017-06-29 | due-trials |
| Reported results | 2011-001111-31 | A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2015-11-18 | due-trials |
| Reported results | 2011-001112-53 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Prim... | 2016-12-05 | due-trials |
| Reported results | 2011-001456-11 | A Multicenter, International, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Assess the Efficacy and Safety of AMG 785 Treatment in Postmenopausal Women With Osteoporosis Est... | 2016-12-28 | due-trials |
| Reported results | 2011-001527-20 | TIMI 57 - A Double-Blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination with HMG-CoA Reductase Inhibitors in ... | 2012-04-05 | due-trials |
| Reported results | 2011-001528-39 | "A Double-blind, Radomized, Placebo-comtrolled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia" "Estudio mul... | 2012-05-16 | due-trials |
| Reported results | 2011-001529-26 | A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA R... | 2012-05-08 | due-trials |
| Reported results | 2011-001544-30 | A Randomized, Placebo and Ezetimibe Controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10 Year Framingham Risk Score of 10... | 2012-03-02 | due-trials |
| Reported results | 2011-001915-29 | A Multicenter Controlled Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of AMG 145 Estudio de extensión abierto (OLE) controlado y multicéntrico para evaluar la seguri... | 2018-06-20 | due-trials |
| Reported results | 2011-002114-36 | Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer. Protocollo con accesso `in aperto` su denosumab nei pazienti con carcinoma in stadio avanzato. | 2018-08-10 | due-trials |
| Reported results Terminated | 2011-002150-31 | An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin alfa in Paediatric Subjects From Birth to Less than 1 Year of Age With Anem... | 2021-05-20 | due-trials |
| Reported results | 2011-002257-61 | An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) ... | 2017-01-03 | due-trials |
| Reported results | 2011-003142-41 | A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis | 2018-02-28 | due-trials |
| Reported results | 2011-003827-37 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects | 2013-10-14 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-004618-40 | An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years With Chronic Kidney Disease and S... | 2016-06-04 | bad-data |
| Reported results | 2011-004844-23 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299) Studio di fase 2, randomizzato, in doppio cie... | 2013-06-14 | due-trials |
| Reported results Terminated | 2011-004845-42 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165) | 2013-05-20 | due-trials |
| Reported results | 2011-004923-11 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Ga... | 2015-09-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-005019-96 | A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) | 2019-08-15 | bad-data |
| Reported results | 2011-005251-13 | A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis Studio rand... | 2018-04-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-005399-40 | A two part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia Part A - Open-label, Single-arm, Multicenter Pilot Stu... | 2014-01-31 | bad-data |
| Reported results | 2011-005400-15 | A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia | 2018-05-11 | due-trials |
| Reported results | 2011-005781-38 | An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE) Blinatumomab in Patients with Relapsed/Refractory Diffuse Large B-Cell... | 2015-09-09 | due-trials |
| Reported results | 2012-000307-32 | A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melan... | 2021-03-09 | due-trials |
| Reported results | 2012-000327-40 | A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and ... | 2015-08-19 | due-trials |
| Reported results | 2012-000529-31 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease | 2018-04-10 | due-trials |
| Reported results Terminated | 2012-000651-13 | A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1 | 2015-10-02 | due-trials |
| Reported results | 2012-000656-34 | A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG... | 2016-10-16 | due-trials |
| Reported results | 2012-000667-24 | A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG... | 2016-10-20 | due-trials |
| Trial is outside EEC, and reported results | 2012-001145-40 | Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trials | bad-data | |
| Trial is outside EEC, and reported results | 2012-001171-37 | A Phase IV Registry of Etanercept in Children With Juvenile Rheumatoid Arthritis | bad-data | |
| Trial is outside EEC, and reported results | 2012-001186-33 | An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis | bad-data | |
| Reported results | 2012-001362-15 | A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Sc... | 2013-10-29 | due-trials |
| Reported results | 2012-001363-70 | A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With ... | 2013-12-04 | due-trials |
| Reported results | 2012-001364-30 | A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Re... | 2013-11-19 | due-trials |
| Reported results | 2012-001365-32 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia | 2013-12-19 | due-trials |
| Reported results | 2012-001382-32 | A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects with Type 2 Diabetes Mellitus | 2012-10-19 | due-trials |
| Reported results | 2012-001398-97 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With... | 2016-11-11 | due-trials |
| Reported results | 2012-001821-28 | A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates | 2015-01-07 | due-trials |
| Reported results | 2012-002805-23 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ... | 2014-06-12 | due-trials |
| Reported results | 2012-002806-31 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ... | 2014-05-09 | due-trials |
| Reported results | 2012-002808-41 | A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialy... | 2016-07-15 | due-trials |
| Reported results | 2012-002948-24 | An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment with AMG 785 in Postmenopausal Women with Osteoporosis Previously Treated with Bisphosphonate Therapy | 2015-05-15 | due-trials |
| Reported results | 2012-003351-11 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility | 2015-05-01 | due-trials |
| Reported results | 2012-004208-37 | A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of Evolocumab (AMG-145) Treatment on Atherosclerotic Disease Burden As Measured By Intravasc... | 2016-07-29 | due-trials |
| Reported results | 2012-004319-29 | A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer | 2017-01-27 | due-trials |
| Reported results | 2012-004357-83 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 | 2018-05-31 | due-trials |
| Reported results | 2012-005331-90 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention | 2019-11-12 | due-trials |
| Reported results | 2013-000192-33 | A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG ... | 2014-12-24 | due-trials |
| Reported results | 2013-000434-35 | A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Ost... | 2015-01-08 | due-trials |
| Reported results | 2013-000525-31 | A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis | 2014-11-19 | due-trials |
| Reported results | 2013-000536-10 | A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute ... | 2017-03-14 | due-trials |
| Reported results | 2013-000537-12 | A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis | 2015-03-18 | due-trials |
| Reported results | 2013-000706-36 | A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leu... | 2017-01-06 | due-trials |
| Reported results | 2013-000723-14 | A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or... | 2017-12-06 | due-trials |
| Completed, but no date, and reported results | 2013-000727-13 | Single arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome | bad-data | |
| Reported results | 2013-000738-36 | A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer | 2015-07-23 | due-trials |
| Reported results | 2013-000935-29 | A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-Co... | 2017-11-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-001277-24 | A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenoc... | 2016-10-10 | bad-data |
| Reported results | 2013-001279-19 | A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis | 2015-07-09 | due-trials |
| Reported results | 2013-001662-42 | A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | 2017-11-28 | due-trials |
| Reported results | 2013-001707-36 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention | 2016-07-06 | due-trials |
| Reported results | 2013-003553-16 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-2 | 2015-10-01 | due-trials |
| Reported results | 2013-003554-25 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-1 | 2015-10-22 | due-trials |
| Reported results | 2013-004136-30 | A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis | 2017-09-28 | due-trials |
| Reported results | 2013-004654-13 | An Open-Label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis | 2016-04-11 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-004958-18 | A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis | 2016-06-23 | bad-data |
| Reported results | 2013-005311-27 | An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334 | 2017-06-26 | due-trials |
| Reported results | 2013-005542-11 | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) | 2019-06-28 | due-trials |
| Exempt, with results | 2013-005543-90 | A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis | 2018-10-08 | not-yet-due |
| Reported results | 2013-005551-32 | A Multicenter, Randomized, Double blind, Placebo controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis | 2016-04-20 | due-trials |
| Reported results | 2013-005552-15 | A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Immunoprofile Intratumoral CD8+ Cell Density in Subjects With Unresected S... | 2020-12-25 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-000184-40 | Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta Prospektivní, multicentrické, jednoramenné klinic... | 2022-03-28 | bad-data |
| Exempt, with results | 2014-000185-22 | A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | 2021-03-11 | not-yet-due |
| Reported results | 2014-001146-13 | A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to... | 2022-04-28 | due-trials |
| Reported results | 2014-001524-30 | A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab | 2018-03-09 | due-trials |
| Other | 2014-001633-84 | Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblasti... | not-yet-due | |
| Reported results | 2014-001700-21 | An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (A... | 2020-01-10 | due-trials |
| Reported results | 2014-001976-75 | A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Backgroun... | 2016-11-11 | due-trials |
| Reported results | 2014-002108-25 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TR... | 2020-07-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-002277-11 | Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Cholesterol... | 2019-12-25 | bad-data |
| Trial is partly outside EEC, and reported results | 2014-002476-92 | A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consol... | 2022-12-05 | bad-data |
| Completed, but no date, and reported results | 2014-002834-30 | A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma | bad-data | |
| Trial is partly outside EEC, and reported results | 2014-003563-38 | A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Di... | 2017-03-15 | bad-data |
| Reported results Terminated | 2014-003701-15 | A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis | 2015-05-28 | due-trials |
| Reported results | 2014-004463-20 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention | 2017-03-20 | due-trials |
| Reported results | 2014-004464-38 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention | 2017-06-19 | due-trials |
| Reported results | 2014-004704-29 | A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis | 2018-08-13 | due-trials |
| Reported results | 2014-004868-38 | A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis. | 2019-12-06 | due-trials |
| Reported results | 2014-004869-24 | A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis. | 2018-07-06 | due-trials |
| Trial is outside EEC, and reported results | 2014-005034-66 | An Open-label, Randomized, Single-dose, 3-period, 3-treatment Crossover Study to Assess the Comparative Bioavailability of 5mg Cinacalcet Capsules to the 30mg Commercial Formulation Cinacalcet Tablets... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005190-36 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors | bad-data | |
| Exempt | 2014-005386-67 | A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and t... | 2023-07-11 | not-yet-due |
| Reported results | 2015-001343-37 | A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evoloc... | 2017-01-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002276-25 | Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From ... | 2021-06-01 | bad-data |
| Reported results | 2015-002322-40 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina | 2017-04-13 | due-trials |
| Trial is outside EEC, and reported results | 2015-002466-22 | A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-met... | bad-data | |
| Exempt, with results | 2015-003011-38 | A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in combination with Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head ... | 2020-08-28 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-003196-29 | A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials | 2021-09-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003645-25 | A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous SystemTumors That ... | 2022-11-29 | bad-data |
| Reported results | 2015-003731-35 | A Randomized Double-blind Placebo Controlled Study Characterizing The Effects of PCSK9 Inhibition On Arterial Wall inflammation in Patients With Elevated Lp(a) | 2018-04-05 | due-trials |
| Reported results | 2015-004711-21 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercho... | 2017-09-05 | due-trials |
| Reported results | 2015-004735-12 | A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mi... | 2020-01-27 | due-trials |
| Reported results | 2015-004780-36 | A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease | 2022-03-24 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-005051-28 | An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Second... | 2018-10-29 | bad-data |
| Exempt, with results | 2016-001080-36 | A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors | 2019-05-17 | not-yet-due |
| Reported results | 2016-002044-16 | A Phase 2/3 Multi-center Study of Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma | 2020-03-12 | due-trials |
| Reported results | 2016-002190-35 | A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL) | 2019-10-28 | due-trials |
| Reported results | 2016-002299-28 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced... | 2020-09-14 | due-trials |
| Trial is partly outside EEC | 2016-003083-39 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis | bad-data | |
| Reported results | 2016-003255-30 | A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transpla... | 2019-09-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003554-33 | A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Myelom... | 2022-04-15 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004066-26 | A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries | 2022-03-04 | bad-data |
| Reported results | 2017-000630-57 | A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention. | 2019-02-04 | due-trials |
| Reported results Terminated | 2017-000675-90 | A Phase 3b, Multicenter, Randomized, Double-blind, Parallel Group, Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate Se... | 2017-05-29 | due-trials |
| Exempt, with results | 2017-000763-33 | A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versus H... | 2022-10-13 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2017-001418-27 | A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | 2022-07-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-001758-32 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Follow-up sulla sicurezza a lungo termine dei pazienti con tumore a cellule giganti del... | 2023-07-27 | bad-data |
| Exempt, with results | 2017-001944-36 | A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy | 2020-05-13 | not-yet-due |
| Exempt | 2017-001997-41 | A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide, with and without Dexamet... | 2023-06-30 | not-yet-due |
| Ongoing | 2017-002397-39 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Epis... | not-yet-due | |
| Ongoing | 2017-002399-23 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chro... | not-yet-due | |
| Trial is outside EEC | 2017-002411-34 | Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to < 18 Years of age With Second... | bad-data | |
| Trial is outside EEC, and reported results | 2017-002659-28 | An open-label, Randomized, Single-dose, 2-Period, "-Treatment Crossover Study to Assess the Bioequivalence of Cinacalcet Capsule (Administered as Six of the 5 mg Cinacalcet Capsules) with 30 mg Commer... | bad-data | |
| Other | 2017-002992-25 | A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Ga... | not-yet-due | |
| Reported results | 2017-003236-37 | High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS) | 2021-01-21 | due-trials |
| Reported results | 2017-003512-40 | A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthc... | 2020-01-08 | due-trials |
| Trial is outside EEC, and reported results | 2017-003778-15 | A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study) | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004972-74 | An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta | 2023-03-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-000550-21 | Multicenter, Single-arm Open-label Extension Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta | 2022-03-28 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-000665-36 | A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A... | 2023-03-31 | bad-data |
| Trial is outside EEC | 2018-000923-15 | A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine | bad-data | |
| Ongoing | 2018-001006-28 | PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-s... | not-yet-due | |
| Reported results | 2018-001233-40 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decr... | 2021-11-29 | due-trials |
| Exempt | 2018-001400-11 | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutat... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-001997-52 | A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis. | 2020-12-22 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002608-15 | A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis | 2022-02-09 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-002735-26 | A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ... | 2023-07-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002748-10 | A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis | 2022-05-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002850-58 | A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PS... | 2021-11-04 | bad-data |
| Exempt, with results | 2018-002879-17 | A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma | 2022-04-21 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2018-002918-12 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderat... | 2023-03-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-003342-16 | A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache Studi... | 2023-06-13 | bad-data |
| Other | 2018-004565-14 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial I... | not-yet-due | |
| Ongoing | 2018-004608-21 | Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents > = 2 to < 18 Years of age With Secondary Hyperpa... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-000328-16 | A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy | 2023-07-25 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-001169-34 | An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd) | 2024-01-19 | bad-data |
| Reported results | 2019-001575-37 | Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311 | 2020-09-07 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-001906-61 | Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy | 2024-02-26 | bad-data |
| Reported results | 2019-002331-28 | Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE) | 2023-01-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-002503-17 | A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration | 2023-01-30 | bad-data |
| Other | 2019-002787-27 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 t... | not-yet-due | |
| Other | 2019-002788-88 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years ... | not-yet-due | |
| Other | 2019-003497-13 | A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis | not-yet-due | |
| Ongoing | 2019-003582-18 | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjec... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-003646-33 | Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase... | 2023-10-26 | bad-data |
| Reported results | 2019-003688-23 | A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lip... | 2022-11-08 | due-trials |
| Exempt | 2019-004780-52 | A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Pre... | not-yet-due | |
| Exempt | 2020-001305-23 | A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | 2023-10-23 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2020-002759-39 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria | 2023-04-13 | bad-data |
| Reported results Terminated | 2020-003057-30 | Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF | 2020-12-10 | due-trials |
| Reported results | 2020-003184-25 | A Phase 3, Multicenter , Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis | 2022-06-03 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-003509-72 | A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy | 2023-05-22 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-004498-29 | Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Ac... | 2023-11-03 | bad-data |
| Exempt | 2020-004721-23 | A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation Protoc... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-005111-51 | A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients with Homozygous Familial Hypercholesterolemia (HoFH) in India | bad-data | |
| Reported results | 2020-005205-42 | A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in ... | 2023-02-28 | due-trials |
| Ongoing, reported early | 2020-005279-11 | A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotorasib) for the Treatment of Subjects in Selected European Countries with Previously Treated Locally Advanced and Unr... | not-yet-due | |
| Reported results | 2021-000542-18 | A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With Con... | 2022-12-19 | due-trials |
| Ongoing | 2021-002537-41 | A Phase 2, Dose-Finding, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severe... | not-yet-due | |
| Ongoing | 2021-002566-40 | A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-002638-18 | A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment | 2022-11-07 | bad-data |
| Other | 2021-003461-35 | A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or... | not-yet-due | |
| Other | 2021-003477-61 | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer ... | not-yet-due | |
| Ongoing | 2021-004008-16 | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previ... | not-yet-due | |
| Other | 2021-005272-19 | EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction | not-yet-due | |
| Exempt | 2021-006386-38 | A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE 301) | 2022-05-27 | not-yet-due |
| Ongoing | 2022-001686-12 | A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis | not-yet-due | |
| Ongoing | 2022-002470-86 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Ty... | not-yet-due | |
| Other | 2022-003024-41 | A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juveni... | not-yet-due |